Is Regorafenib effective for colon cancer?

Colon cancer is a cancer that starts in the colon(large intestine) or rectum, the organs that make up the lower part of the digestive system. Regorafenib (Regorafenib) is an oral multikinase inhibitor approved for refractory colorectal cancer. Although structurally similar to sorafenib, it more effectively inhibits a broader range of key growth receptor pathways, including those that regulate angiogenesis and abnormal cell proliferation. In an international, randomized, placebo-controlled, phase III study of 760 patients, 41% of patients achieved stable disease and only 1% achieved remission. Regofenibproved to be tolerable, with side effects characteristic of other small molecule inhibitors.